Lates News

Chinese biopharmaceutical company announced that apatinib is a selective HER2 small molecule inhibitor jointly developed by Boehringer Ingelheim, which has been granted priority review and breakthrough therapy designation by the CDE for the indication of HER2-mutant advanced non-small cell lung cancer (NSCLC) in previously treated patients. In August of this year, apatinib received accelerated approval from the FDA in the United States.